The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study
Authors:
- 13 February 2018
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 78 (7) , 491-497
Abstract
Background: The present of metastases is a poor prognostic factor in prostate cancer, but the prognostic impact of different distant metastases pattern is unclear. The aim of this study is to investigate the impact of different distant metastases pattern on the survival of patients with stage IV prostate cancer.Methods: Data queried for this study include prostate cancer (2010‐2014) from the Surveillance, Epidemiology, and End Results (SEER) program. Metastatic distribution information was provided for bone, brain, liver and lung. The overall survival was calculated by the Kaplan‐Meier method. Multivariable Cox regression models were used to analyze survival outcome and risk factors.Results: A total of 265 900 eligible patients were identified from SEER database. Among these patients, stage of IV prostate cancer accounted for 7.53% (20 034/265 900) at diagnosis. Patients who suffered metastasis to either one of the four organs occupied 61.24% (12 268/20 034) in stage of IV patients. Comparing with other three single metastases, the patients with liver metastasis exhibited worst OS whose mean survival was 17.529 months (P < 0.001). The mean survival of metastases with bong and lung was 25.238 months, which was the best survival of the six forms with two metastatic sites (P < 0.001). The results of univariate survival analysis showed that metastatic forms, race, N‐classification and differentiated grade did not have impact on the overall survival of patients with three metastatic sites (all, P > 0.05).Conclusions: In analysis of both one and two metastatic sites, patients with liver metastasis seemed to have worse survival outcome. On the other hand, bone metastasis had better outcome than other three visceral metastases. Knowledge of these differences in metastatic patterns may help to better guide pre‐treatment evaluation of prostate cancer and make determination regarding curative‐intent interventions.Keywords
Funding Information
- National Natural Science Foundation of China (81502541)
This publication has 23 references indexed in Scilit:
- Distribution of metastatic sites in patients with prostate cancer: A population‐based analysisThe Prostate, 2013
- Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic NomogramsEuropean Urology, 2013
- Atypical Metastases From Prostate Cancer: 10-Year Experience at a Single InstitutionAmerican Journal of Roentgenology, 2012
- Methylation signature of lymph node metastases in breast cancer patientsBMC Cancer, 2012
- Global Patterns of Cancer Incidence and Mortality Rates and TrendsCancer Epidemiology, Biomarkers & Prevention, 2010
- Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological studyThe Lancet Oncology, 2008
- Small Cell Carcinoma of the ProstateAmerican Journal of Surgical Pathology, 2008
- A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study AnalysisClinical Cancer Research, 2007
- Liver metastases in prostate carcinoma: clinical characteristics and outcomeBJU International, 2006
- The metastatic cascade in prostate cancerSurgical Oncology, 2006